Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Second primary cancers in patients with invasive and in situ squamous cell skin carcinoma, Kaposi sarcoma and Merkel cell carcinoma: role for immune mechanisms?

Chattopadhyay S, Hemminki A, Försti A, Sundquist K, Sundquist J, Hemminki K.

J Invest Dermatol. 2019 Jul 6. pii: S0022-202X(19)31854-8. doi: 10.1016/j.jid.2019.04.031. [Epub ahead of print]

PMID:
31288011
2.

Second primary cancers in non-Hodgkin lymphoma: Family history and survival.

Chattopadhyay S, Zheng G, Sud A, Sundquist K, Sundquist J, Försti A, Houlston R, Hemminki A, Hemminki K.

Int J Cancer. 2019 May 4. doi: 10.1002/ijc.32391. [Epub ahead of print]

PMID:
31054153
3.

Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients.

Zheng G, Chattopadhyay S, Sud A, Sundquist K, Sundquist J, Försti A, Houlston RS, Hemminki A, Hemminki K.

Blood Cancer J. 2019 Mar 26;9(4):40. doi: 10.1038/s41408-019-0201-0. No abstract available.

4.

Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.

Cervera-Carrascon V, Havunen R, Hemminki A.

Expert Opin Biol Ther. 2019 May;19(5):443-455. doi: 10.1080/14712598.2019.1595582. Epub 2019 Mar 25.

PMID:
30905206
5.

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.

Zheng G, Chattopadhyay S, Sud A, Sundquist K, Sundquist J, Försti A, Houlston R, Hemminki A, Hemminki K.

Br J Haematol. 2019 Apr;185(2):232-239. doi: 10.1111/bjh.15777. Epub 2019 Jan 31.

PMID:
30706458
6.

Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs.

Heiniö C, Sorsa S, Siurala M, Grönberg-Vähä-Koskela S, Havunen R, Haavisto E, Koski A, Hemminki O, Zafar S, Cervera-Carrascon V, Munaro E, Kanerva A, Hemminki A.

Hum Gene Ther. 2019 Jun;30(6):740-752. doi: 10.1089/hum.2018.240. Epub 2019 Feb 28.

PMID:
30672366
7.

Familial Associations of Colon and Rectal Cancers With Other Cancers.

Yu H, Hemminki A, Sundquist K, Hemminki K.

Dis Colon Rectum. 2019 Feb;62(2):189-195. doi: 10.1097/DCR.0000000000001262.

PMID:
30640834
8.

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.

Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2018 Nov 6;11:109-121. doi: 10.1016/j.omto.2018.10.005. eCollection 2018 Dec 21.

9.

Second primary cancer after female breast cancer: Familial risks and cause of death.

Zheng G, Hemminki A, Försti A, Sundquist J, Sundquist K, Hemminki K.

Cancer Med. 2019 Jan;8(1):400-407. doi: 10.1002/cam4.1899. Epub 2018 Nov 26.

10.

CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy.

Zafar S, Sorsa S, Siurala M, Hemminki O, Havunen R, Cervera-Carrascon V, Santos JM, Wang H, Lieber A, De Gruijl T, Kanerva A, Hemminki A.

Oncoimmunology. 2018 Aug 15;7(10):e1490856. doi: 10.1080/2162402X.2018.1490856. eCollection 2018.

PMID:
30386680
11.

Second primary cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction.

Chattopadhyay S, Sud A, Zheng G, Yu H, Sundquist K, Sundquist J, Försti A, Houlston R, Hemminki A, Hemminki K.

Int J Cancer. 2018 Nov 15;143(10):2449-2457. doi: 10.1002/ijc.31801. Epub 2018 Sep 21.

PMID:
30238973
12.

Multiple myeloma: family history and mortality in second primary cancers.

Chattopadhyay S, Yu H, Sud A, Sundquist J, Försti A, Hemminki A, Hemminki K.

Blood Cancer J. 2018 Aug 7;8(8):75. doi: 10.1038/s41408-018-0108-1. No abstract available.

13.

Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden.

Chattopadhyay S, Zheng G, Sud A, Yu H, Sundquist K, Sundquist J, Försti A, Hemminki A, Houlston R, Hemminki K.

Lancet Haematol. 2018 Aug;5(8):e368-e377. doi: 10.1016/S2352-3026(18)30108-X.

PMID:
30075833
14.

Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.

Santos JM, Cervera-Carrascon V, Havunen R, Zafar S, Siurala M, Sorsa S, Anttila M, Kanerva A, Hemminki A.

Mol Ther. 2018 Sep 5;26(9):2243-2254. doi: 10.1016/j.ymthe.2018.06.001. Epub 2018 Jul 13.

PMID:
30017877
15.

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.

Hemminki O, Oksanen M, Taipale K, Liikanen I, Koski A, Joensuu T, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2018 Apr 22;9:41-50. doi: 10.1016/j.omto.2018.04.003. eCollection 2018 Jun 29.

16.

TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A, Hemminki A.

Oncoimmunology. 2018 Apr 9;7(5):e1412902. doi: 10.1080/2162402X.2017.1412902. eCollection 2018.

17.

Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.

Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.

JCI Insight. 2018 Apr 5;3(7). pii: 99573. doi: 10.1172/jci.insight.99573. eCollection 2018 Apr 5.

18.

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients.

Taipale K, Tähtinen S, Havunen R, Koski A, Liikanen I, Pakarinen P, Koivisto-Korander R, Kankainen M, Joensuu T, Kanerva A, Hemminki A.

Oncotarget. 2018 Jan 5;9(5):6320-6335. doi: 10.18632/oncotarget.23967. eCollection 2018 Jan 19.

19.

Familial associations of male breast cancer with other cancers.

Zheng G, Yu H, Hemminki A, Försti A, Sundquist K, Hemminki K.

Breast Cancer Res Treat. 2017 Dec;166(3):897-902. doi: 10.1007/s10549-017-4468-1. Epub 2017 Aug 23.

PMID:
28836035
20.

Familial associations of female breast cancer with other cancers.

Zheng G, Yu H, Hemminki A, Försti A, Sundquist K, Hemminki K.

Int J Cancer. 2017 Dec 1;141(11):2253-2259. doi: 10.1002/ijc.30927. Epub 2017 Aug 26.

21.

Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.

Kuryk L, Vassilev L, Ranki T, Hemminki A, Karioja-Kallio A, Levälampi O, Vuolanto A, Cerullo V, Pesonen S.

PLoS One. 2017 Aug 10;12(8):e0182715. doi: 10.1371/journal.pone.0182715. eCollection 2017.

22.

Familial Associations of Colorectal Cancer with Other Cancers.

Yu H, Hemminki A, Sundquist K, Hemminki K.

Sci Rep. 2017 Jul 12;7(1):5243. doi: 10.1038/s41598-017-05732-z.

23.

Other cancers in lung cancer families are overwhelmingly smoking-related cancers.

Yu H, Frank C, Hemminki A, Sundquist K, Hemminki K.

ERJ Open Res. 2017 Jun 27;3(2). pii: 00006-2017. doi: 10.1183/23120541.00006-2017. eCollection 2017 Apr.

24.

Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.

Santos JM, Havunen R, Siurala M, Cervera-Carrascon V, Tähtinen S, Sorsa S, Anttila M, Karell P, Kanerva A, Hemminki A.

Int J Cancer. 2017 Oct 1;141(7):1458-1468. doi: 10.1002/ijc.30839. Epub 2017 Jun 29.

25.

Genetics of gallbladder cancer.

Hemminki K, Hemminki A, Försti A, Sundquist K, Li X.

Lancet Oncol. 2017 Jun;18(6):e296. doi: 10.1016/S1470-2045(17)30324-8. No abstract available.

PMID:
28593851
26.

Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System.

Cerullo V, Capasso C, Vaha-Koskela M, Hemminki O, Hemminki A.

Curr Cancer Drug Targets. 2018;18(2):124-138. doi: 10.2174/1568009617666170502152352. Review.

PMID:
28464762
27.

TILT Biotherapeutics.

Hemminki A.

Hum Vaccin Immunother. 2017 May 4;13(5):970-971. doi: 10.1080/21645515.2017.1298962. Epub 2017 Mar 1. No abstract available.

28.

Power and limits of modern cancer diagnostics: cancer of unknown primary.

Hemminki K, Liu H, Hemminki A, Sundquist J.

Ann Oncol. 2017 Dec 1;28(12):3112. doi: 10.1093/annonc/mdx057. No abstract available.

PMID:
28368513
29.

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.

Havunen R, Siurala M, Sorsa S, Grönberg-Vähä-Koskela S, Behr M, Tähtinen S, Santos JM, Karell P, Rusanen J, Nettelbeck DM, Ehrhardt A, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2016 Dec 31;4:77-86. doi: 10.1016/j.omto.2016.12.004. eCollection 2017 Mar 17.

30.

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.

Zafar S, Parviainen S, Siurala M, Hemminki O, Havunen R, Tähtinen S, Bramante S, Vassilev L, Wang H, Lieber A, Hemmi S, de Gruijl T, Kanerva A, Hemminki A.

Oncoimmunology. 2016 Dec 7;6(2):e1265717. doi: 10.1080/2162402X.2016.1265717. eCollection 2017.

31.

Risk of other Cancers in Families with Melanoma: Novel Familial Links.

Frank C, Sundquist J, Hemminki A, Hemminki K.

Sci Rep. 2017 Feb 15;7:42601. doi: 10.1038/srep42601.

32.

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.

Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vähä-Koskela M, Savola P, Tähtinen S, Saikko L, Hemminki A, Kovanen PE, Porkka K, Lee FY, Mustjoki S.

Cancer Immunol Res. 2017 Feb;5(2):157-169. doi: 10.1158/2326-6066.CIR-16-0061-T. Epub 2017 Jan 10.

33.

Concordant and discordant familial cancer: Familial risks, proportions and population impact.

Frank C, Sundquist J, Yu H, Hemminki A, Hemminki K.

Int J Cancer. 2017 Apr 1;140(7):1510-1516. doi: 10.1002/ijc.30583. Epub 2017 Jan 20.

34.

Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation.

Joensuu T, Joensuu G, Kairemo K, Kiljunen T, Riener M, Aaltonen A, Ala-Opas M, Kangasmäki A, Alanko T, Taipale L, Hervonen P, Bützow A, Virgolini I, Hemminki A.

Anticancer Res. 2016 Dec;36(12):6439-6447.

PMID:
27919966
35.

Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma".

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther. 2016 Nov;24(11):2033. doi: 10.1038/mt.2016.196. No abstract available.

36.

T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.

Tähtinen S, Blattner C, Vähä-Koskela M, Saha D, Siurala M, Parviainen S, Utikal J, Kanerva A, Umansky V, Hemminki A.

J Immunother. 2016 Nov/Dec;39(9):343-354.

PMID:
27741089
37.

Common cancers share familial susceptibility: implications for cancer genetics and counselling.

Yu H, Frank C, Sundquist J, Hemminki A, Hemminki K.

J Med Genet. 2017 Apr;54(4):248-253. doi: 10.1136/jmedgenet-2016-103932. Epub 2016 Sep 20.

PMID:
27651446
38.

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity.

Hirvinen M, Capasso C, Guse K, Garofalo M, Vitale A, Ahonen M, Kuryk L, Vähä-Koskela M, Hemminki A, Fortino V, Greco D, Cerullo V.

Mol Ther Oncolytics. 2016 Mar 23;3:16002. doi: 10.1038/mto.2016.2. eCollection 2016.

39.

The epidemiology of metastases in neuroendocrine tumors.

Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K.

Int J Cancer. 2016 Dec 15;139(12):2679-2686. doi: 10.1002/ijc.30400. Epub 2016 Sep 9.

40.

Familial Associations Between Prostate Cancer and Other Cancers.

Frank C, Sundquist J, Hemminki A, Hemminki K.

Eur Urol. 2017 Feb;71(2):162-165. doi: 10.1016/j.eururo.2016.07.031. Epub 2016 Aug 4.

PMID:
27498599
41.

Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.

Siurala M, Vähä-Koskela M, Havunen R, Tähtinen S, Bramante S, Parviainen S, Mathis JM, Kanerva A, Hemminki A.

Oncoimmunology. 2016 Feb 18;5(5):e1136046. doi: 10.1080/2162402X.2015.1136046. eCollection 2016 May.

42.

Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.

Liikanen I, Tähtinen S, Guse K, Gutmann T, Savola P, Oksanen M, Kanerva A, Hemminki A.

Mol Cancer Ther. 2016 Sep;15(9):2259-69. doi: 10.1158/1535-7163.MCT-15-0819. Epub 2016 Jul 25.

43.

Metastatic spread in patients with gastric cancer.

Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K.

Oncotarget. 2016 Aug 9;7(32):52307-52316. doi: 10.18632/oncotarget.10740.

44.

Patterns of metastasis in colon and rectal cancer.

Riihimäki M, Hemminki A, Sundquist J, Hemminki K.

Sci Rep. 2016 Jul 15;6:29765. doi: 10.1038/srep29765.

45.

Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther. 2016 Aug;24(8):1435-43. doi: 10.1038/mt.2016.137. Epub 2016 Jun 30. Erratum in: Mol Ther. 2016 Nov;24(11):2033.

46.

Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.

Bramante S, Koski A, Liikanen I, Vassilev L, Oksanen M, Siurala M, Heiskanen R, Hakonen T, Joensuu T, Kanerva A, Pesonen S, Hemminki A.

Oncoimmunology. 2015 Aug 27;5(2):e1078057. eCollection 2016 Feb.

47.

A century of oncolysis evolves into oncolytic immunotherapy.

Hemminki O, Hemminki A.

Oncoimmunology. 2015 Aug 12;5(2):e1074377. eCollection 2016 Feb.

48.

Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.

Taipale K, Liikanen I, Koski A, Heiskanen R, Kanerva A, Hemminki O, Oksanen M, Grönberg-Vähä-Koskela S, Hemminki K, Joensuu T, Hemminki A.

Mol Ther. 2016 Aug;24(7):1323-32. doi: 10.1038/mt.2016.67. Epub 2016 Apr 4.

49.

Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.

Ranki T, Pesonen S, Hemminki A, Partanen K, Kairemo K, Alanko T, Lundin J, Linder N, Turkki R, Ristimäki A, Jäger E, Karbach J, Wahle C, Kankainen M, Backman C, von Euler M, Haavisto E, Hakonen T, Heiskanen R, Jaderberg M, Juhila J, Priha P, Suoranta L, Vassilev L, Vuolanto A, Joensuu T.

J Immunother Cancer. 2016 Mar 15;4:17. doi: 10.1186/s40425-016-0121-5. eCollection 2016.

50.

Location of metastases in cancer of unknown primary are not random and signal familial clustering.

Hemminki K, Sundquist K, Sundquist J, Hemminki A, Ji J.

Sci Rep. 2016 Mar 9;6:22891. doi: 10.1038/srep22891.

Supplemental Content

Loading ...
Support Center